Cutaneous T-cell lymphoma - null regimens

The purpose of this page is to provide references to "null therapy" such as placebo and observation. While not clinically relevant, these references provide further insight into the historical development of the treatment landscape. See the main CTCL page for current regimens.

Relapsed or refractory

Placebo

Regimen

Study	Dates of enrollment	Evidence	Comparator	Comparative Efficacy
Prince et al. 2010 (L4389-11)	NR	Phase 3 (C)	Denileukin diftitox	Inferior PFS

References

1. L4389-11: Prince HM, Duvic M, Martin A, Sterry W, Assaf C, Sun Y, Straus D, Acosta M, Negro-Vilar A. Phase III placebo-controlled trial of denileukin diftitox for patients with cutaneous T-cell lymphoma. J Clin Oncol. 2010 Apr 10;28(11):1870-7. Epub 2010 Mar 8. link to original article contains dosing details in manuscript PubMed Clinical Trial Registry